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ABSTRACT 
 
Systemic lupus erythematosus (SLE) patients have an increased risk of atherosclerosis. Identi-
fication of at-risk patients and the pathogenesis of atherosclerosis in SLE remain elusive. 
Paraoxonase 1 (PON1) and anti-apolipoprotein A-I antibody (anti-Apo A-I) appear to have a 
potential role in premature atherosclerosis in SLE. The aim of this work was to study PON1 
activity and anti-Apo A-I antibody in SLE female patients and to demonstrate their relations 
to disease activity as well as disease related damage. Forty SLE female patients and 40 appar-
ently healthy volunteers were included. Anti-Apo A-I antibodies levels and PON1 activity 
levels were assessed. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and 
systemic Lupus International Collaboration Clinics (SLICC)/American College of Rheuma-
tology (ACR) damage index were preformed in all patients. Compared with controls, SLE pa-
tients showed significantly lower PON1 activity and significantly higher titers of anti-Apo  
A-I. Anti-Apo A-I antibody titers correlated inversely with PON1 activity. Elevated titers of 
anti-Apo A-I antibody and reduced PON activity were related to increased SLEDAI and 
(SLICC/ACR) damage index scores. We concluded that there is decreased PON1 activity and 
formation of anti-Apo A-I antibodies in female patients with SLE. SLE-disease activity as-
sessed by SLEDAI and SLE disease related organ damage assessed by SLICC/ACR damage 
index are negatively correlated with PON1 activity and positively correlated with anti-Apo  
A-I antibodies. PON1 activity and anti-Apo A-I antibodies might be involved in the patho-
genesis of atherosclerosis in SLE patients. 
 
Keywords: SLE, anti-apolipoprotein A-I antibodies, paraoxonase 1 
 
 
 
EXCLI Journal 2013;12:719-732 – ISSN 1611-2156 
Received: May 02, 2013, accepted: July 16, 2013, published: August 15, 2013 
 
 
720 
INTRODUCTION 
Systemic lupus erythematosus (SLE) is 
a chronic inflammatory disorder character-
ized by the production of autoantibodies 
against a variety of self antigens. The clini-
cal presentation of SLE varies widely with 
periodic flare-ups (Chiu et al., 2012). De-
spite improvement in survival rates of pa-
tients, the standardized mortality ratios are 
still 3-fold higher than for the general popu-
lation (Souza et al., 2012). 
Patients with SLE have a significantly 
increased risk of cardiovascular diseases 
(CVD) and mortality, particularly related to 
premature atherosclerosis. The exact etiolo-
gy of premature atherosclerosis in SLE re-
mains unclear. Traditional cardiac risk fac-
tors as defined by the Framingham Heart 
Studies, such as hypertension, hyper-
lipidemia, smoking, obesity and DM appear 
to play a critical role in the development of 
atherosclerosis, but these factors alone can-
not adequately explain the increased inci-
dence of atherosclerotic CVD in SLE. 
Nowadays, it is widely accepted that accel-
erated atherosclerosis in SLE is of a com-
plex cross-talk between traditional and non-
traditional SLE-related risk factors (Belibou 
et al., 2012). 
Systemic lupus erythematosus-related 
risk factors contributing to CVD are at-
tributed to long-term inflammatory burden 
and immune abnormalities including innate 
immune responses, immune-cell activation, 
autoantibodies and increased levels of pro-
inflammatory cytokines. In addition, oxida-
tive stress, adipokines, dysfunctional lipids 
and multiple SLE therapeutics appear to 
affect the development and progression of 
atherosclerosis (Skaggs et al., 2012). 
Accumulating evidence has shown that 
atherosclerosis is not just a cholesterol stor-
age disorder in vasculature but a sustained, 
dynamic, and chronic inflammatory process 
(Chiu et al., 2012). Altered immune system 
function is recognized as the primary con-
tributor to both the initiation and progres-
sion of atherosclerosis (Skaggs et al., 2012).  
Epidemiological studies have consist-
ently shown that plasma HDL inversely 
correlated with the incidence of CVD in the 
general population. This relationship is ac-
tually quite complex and involves not only 
the quantity, but also the quality of HDL. 
The importance of HDL as a protective 
molecule against atherogenesis could be 
partly explained by its constituents mainly, 
paraoxonase (PON1) and apolipoprotein  
A-I (Apo A-I) (Guo et al., 2012). 
PON1is an enzyme synthesized in the 
liver and is bounded to HDL particles in 
blood. PON1 appears to contribute to the 
antioxidant and anti-atherosclerotic capabil-
ities of HDL (Quillen et al., 2012). Howev-
er, the exact mechanism of PON1’s protec-
tive action and its endogenous substrate 
remain elusive (Gugliucci et al., 2012). 
Apo A-I is the major protein component 
of HDL and is widely considered to be re-
sponsible for the anti-atherogenic and anti-
thrombotic effects of HDL by promoting 
cellular cholesterol efflux and exerting anti-
oxidative and anti-inflammatory effects 
(Eren et al., 2012). Apo A-I exerts anti-
oxidant properties by stabilizing PON1 
(Narshi et al., 2011). There is an emerging 
evidence of the presence of anti-Apo A-I 
antibodies and the reduction in the plasma 
levels of PON1 in SLE patients, thus inter-
fering with the protective functions of HDL 
favoring atherogenesis (Batuca et al., 
2009). 
The aim of this work was to study 
PON1 activity and anti-Apo A-I antibody in 
SLE female patients and to demonstrate 
their relations to disease activity as well as 
disease related damage. 
 
MATERIAL AND METHODS 
Subjects 
Eighty participants were included; they 
were divided into two groups. 
Patient Group: Forty SLE premenopau-
sal female patients diagnosed according to 
the ACR revised criteria of SLE (Hochberg, 
1997). Their age ranged between 18 to 46 
years and the SLE disease duration extend-
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ed between 0.5 and 15 years. Patients were 
selected from attendants of Rheumatology 
and Rehabilitation outpatient clinic and in-
patient department of Kasr El-Aini hospital 
(Cairo University). Factors known to influ-
ence PON1 activity or induce premature 
atherosclerosis were excluded namely, 
smoking, diabetes mellitus, chronic renal 
failure, nephrotic syndrome and antiphos-
pholipid syndrome. Patients on lipid lower-
ing drugs, known cases of primary 
dyslipidemia and hypothyroidism and fami-
ly history of CVD were excluded too. 
Control Group: Forty apparently healthy 
age and culture matched female volunteers 
served as control group. Their age ranged 
between 18 to 47 years. 
An informed consent was obtained from 
all participants in the study, and the study 
was approved by the ethical committees of 
Cairo University and National Research 
Center. 
 
Methods 
All participants were subjected to thor-
ough history taking and physical examina-
tion. Blood samples were withdrawn from 
each participant after fasting for 12-14 
hours. The following were determined: 
complete blood count using coulter counter 
(T660), erythrocyte sedimentation rate by 
Westergren method (Dacie and Lewis, 
1985), serum AST and ALT, blood urea 
and serum creatinine by automated Hitachi 
911, urine analysis including: proteinuria, 
red blood cells, white blood cells, crystals 
and casts, serum lipid profile: HDL 
(Burstein et al., 1970), triglycerides, total 
cholesterol (Jacobs and VanDemark, 1960; 
Richmond, 1973) and LDL concentration 
was estimated indirectly using the Frie-
dewald equation: LDL = TC – HDL – (TG / 
5) (Rifai and Warnick, 2006), estimation of 
total albumin in 24 hours urine, anti-nuclear 
antibodies and anti-dsDNA antibodies by 
indirect immunoflourescence technique 
(Aitcheston and Tan, 1982; Nakamura et 
al., 1984), serum complement level (C3 and 
C4) quantitatively (Harris et al., 1986) and 
Lupus anticoagulants (Thiagarajan et al., 
1986). 
 
Determination of anti-Apo A-I antibodies 
level in the plasma 
96-well plates (PolySorp) were half-
coated for 1 hour at 37 °C with 10 mg/ml 
human Apo A-I (Sigma-Aldrich) in 70 % 
ethanol. Blocking was performed using 
phosphate buffered saline containing 1 % 
albumin from bovine serum for 1 hour at 
37 °C. A hundred microlitres of the samples 
(1:300 dilutions in blocking agent) and pos-
itive control were added to duplicate wells 
in both halves of the plate for 1 hour at 
37 °C. After washing, alkaline phosphatase-
conjugated anti-human IgG (1:1000 in the 
blocking agent) was added for 1 hour. p-
Nitrophenyl phosphate (1:5000 in bicar-
bonate buffer, pH 9.8) was added and incu-
bated at 37 °C for color development and 
the absorbance read at 405 nm after 1 hour. 
All assays were validated by the inclusion 
of internal quality control samples of 
known activity. The results were expressed 
as the percentage of the positive control 
present in each plate after subtraction from 
the background in the uncoated half of the 
plate. Inter-/intra-plate coefficients of varia-
tion were < 10 % (Batuca et al., 2009). 
 
Determination of paraoxonase1 activity 
Serum paraoxonase 1/Arylesterase (the 
activity toward phenyl acetate) was deter-
mined spectrophotometrically at 270 nm 
with phenyl acetate used as the substrate. 
The assay mixture included 1.0 mmol/L of 
phenyl acetate and 0.9 mmol/L CaCl2 in 
20 mmol/L Tris HCl, pH 8.0 at 25 °C. Non-
enzymatic hydrolysis of phenyl acetate was 
subtracted from the total rate of hydrolysis. 
The E270 for the reaction is 1310 mol/L-1 
cm-1. The results are expressed in U/ml; 1 U 
hydrolyzes 1 µmol of phenyl acetate/minute 
(Aviram et al., 2000). 
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Assessment of disease activity and disease 
related damage 
Assessment of disease activity was done 
using Systemic Lupus Erythematosus Dis-
ease Activity Index (SLEDAI) (Bombardier 
et al., 1992). Assessment of disease related 
damage was done using using Systemic 
Lupus International Collaborative Clin-
ics/American College of Rheumatology 
(SLEICC/ACR) Damage Index (Gladman 
et al., 1996). 
 
Statistical analysis 
Data were statistically described in 
terms of mean  standard deviation ( SD). 
Comparison between cases and control 
groups was done using Student t test for 
independent samples. Correlation between 
various variables was done using Pearson 
moment correlation equation for linear rela-
tion in normally distributed variables and 
Spearman rank correlation equation for 
non-normal variables. p values less than 
0.05 was considered statistically significant. 
All statistical calculations were done using 
computer programs SPSS (Statistical Pack-
age for the Social Science; SPSS Inc., Chi-
cago, IL, USA) version 15 for Microsoft 
Windows. 
 
RESULTS 
The statistical analyses of the demo-
graphic and laboratory characteristics of the 
participants, of the main clinical data of 
SLE patients and of the drugs given to them 
are shown in Tables 1, 2 and 3 respectively.  
The mean serum Paraoxonase 1 (PON1) 
activity level in SLE patients was signifi-
cantly lower than its mean level in the con-
trol. The mean plasma anti-Apo A-I anti-
body level in SLE patients was significantly 
higher than its mean level in the controls 
(Table 4). A significant negative correlation 
was obtained between the serum PON1 ac-
tivity level and the plasma anti-Apo A-I 
level in SLE patient (Figure 1). 
 
 
Table 1: Demographic & laboratory characteristics of the participants 
 
Patients (sum=40) Controls (sum=40) 
Signif. 
Mean ± SD Range Mean ± SD Range 
Age (Years) 28.3 ± 7.0 18 - 46 28.4 ± 7.5 18 - 47 NS 
BMI (Kg/m2) 26.1 ± 4.4 19.7 - 44.4 26.3 ± 4.0 20.8 - 42.6 NS 
Hb (gm/dl) 10.7 ± 2.0 5.9 - 13.4 12.4 ± 0.8 10.5 - 13.8 0.000* 
TLC (x103/μl) 6.2 ± 2.3 1.6 - 11.7 6.9 ± 1.9 4.1 - 11.1 NS 
Platelets 
(x103/μl) 256.8 ± 88.6 75 - 421 263.1 ± 53.0 172 - 371 NS 
ESR (mm/hour) 52.5 ± 24.7 10 - 120 14.5 ± 6.0 5 - 26 0.000* 
ALT (U/L) 23.5 ± 12.0 7 - 73 25.4 ± 12.5 5 - 65 NS 
AST (U/L) 26.1 ± 11.9 9 - 69 27.4 ± 15.3 11 - 80 NS 
Urea (mg/dl) 36.0 ± 16.3 13 - 90 31.8 ± 7.1 13 - 43 NS 
Creatinine (mg/dl) 0.79 ± 0.37 0.4 - 2.4 0.73 ± 0.2 0.5 - 1.2 NS 
TC (mg/dl) 259.0 ± 68.7 143 - 376 159.0 ± 38.1 73 - 240 0.000* 
TG (mg/dl) 228.2 ± 83.2 96 - 428 127.0 ± 36.0 76 - 213 0.000* 
HDL (mg/dl) 41.8 ± 6.9 31 - 60 59.5 ± 10.5 39 - 78 0.000* 
LDL (mg/dl) 171.5 ± 54.1 81 - 265 74.8 ± 24.7 19 - 120 0.000* 
C3 (mg/dl) 92.2 ± 52.5 13.5 - 185 135.4 ± 25.4 90.3 - 185 0.000* 
C4 (mg/dl) 16.7 ± 12.7 2.5 - 43 28.5 ± 8.2 12.1 - 42 0.000* 
*: significant (p < 0.05) 
BMI = Body mass index, Hb = Hemoglobin, NS: Non significant, Signif. = Significance,  
TC = Total cholesterol, TG = Triglyceride, TLC = Total leukocyte count 
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Table 2: Main clinical data of SLE patients 
Clinical data Patients 
(Sum=40) 
Percen-
tage 
Musculoskeletal 
manifestation 37 92.5 % 
Arthralgia 37 92.5 % 
Frank arthritis 28 70 % 
Avascular necrosis 
of bone 
6 15 % 
Mucocutaneous 
manifestation 32 80 % 
Hair fall 23 57.5 % 
Oral ulcer 22 55 % 
Skin rash 20 50 % 
Photosensitivity 18 45 % 
Constitutional  
manifestation 30 75 % 
Fatigue 24 60 % 
Fever 21 52.5 % 
Nephritis 26 65 % 
Serositis 16 40 % 
Central nervous 
system manifesta-
tion 
12 30 % 
Psychosis 7 17.5 % 
Convulsions 6 15 % 
Hepatomegaly 10 25 % 
Vasculitis 7 17.5 % 
Skin vasculitis 5 12.5 % 
Retinal vasculitis 3 7.5 % 
Ocular 
manifestations 7 17.5 % 
Retinal vasculitis 3 7.5 % 
Secondary 
Sjogren's syndrome 
4 10 % 
Splenomegaly 5 15 % 
 
 
Table 3: Drugs administrated by SLE patients 
Medications Patients (Sum=40) 
Steroids
< 10 mg/day
10 – 25 mg/day
> 25 mg/day
40 (100 %) 
4 (10 %) 
18 (45.5 %) 
18 (45.5 %) 
Antimalarials 31 (77.5 %) 
Azathioprine 22 (55 %) 
Cyclophosphamide 9 (22.5 %) 
 
r = -0.506          P < 0.001 
Figure 1: Correlation between the PON1 activi-
ty and anti-Apo A-I levels 
 
 
The correlative studies between 
SLEDAI scores and PON1 activity as well 
as anti-Apo A-I antibody showed a marked 
significant negative correlation between 
SLEDAI scores and PON1 and a significant 
positive correlation with the anti-Apo A-I 
antibody. The correlative studies also 
showed a marked significant negative cor-
relation between SLICC/ACR scores and 
PON1 activity, whereas a significant posi-
tive correlation with the anti-Apo A-I anti-
body was obtained (Table 5). 
Non significant correlations were ob-
tained between both PON1 and anti-Apo  
A-I levels in SLE patient and the demo-
graphic characteristics and the laboratory 
investigations of these patients. However, 
significant negative correlations were ob-
tained between C3, C4 and anti-Apo A-I 
antibodies levels but not with PON1 activi-
ty (Table 6). Again, non significant correla-
tions were obtained between both PON1 
activity and anti-Apo A-I of the patients 
and the dose and the duration of the drug 
used (Table 7). 
Statistically significant differences were 
present between PON1 activity levels in the 
presence and absence of constitutional and 
CNS manifestations. Otherwise, no signifi-
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cant differences were present between 
PON1 activity levels in the presence and 
absence of other disease manifestations 
(Table 8). Statistically non-significant dif-
ferences were present between the Anti-
Apo A-I levels in the presence or absence 
of all the studied disease manifestations 
(Table 9). 
 
 
Table 4: PON1 activity and anti-Apo A-I antibody levels in SLE patients and controls 
 Cases Controls p value 
 Mean ± SD Range Mean ± SD Range  
PON1 (U /ml) 95.9 ± 8.1 78.1 - 108.4 126.2 ± 7.7 99.8 - 138.1 0.001* 
Anti-Apo A-I (U/L) 33.5 ± 6.9 20.1 - 54.3 24.5 ± 6.5 17.5 - 39.6 0.000* 
*: significant (p < 0.05) 
 
 
Table 5: Correlation between PON1 activity and Anti-Apo A-I antibody levels in SLE patients and the 
SLEDAI and SLICC scores 
Studied parameter Studied parameter r p value 
PON1(U/ml) SLEDAI scores -0.402 0.010* 
Anti-Apo A-I (U /L) SLEDAI scores 0.602 0.000* 
PON1(U/ml) SLICC scores -0.715 0.013* 
Anti-Apo A-I (U/L) SLICC scores 0.763 0.006* 
*: significant (p < 0.05) 
 
Table 6: Correlation between PON1 activity, anti-Apo A-I and the demographic characteristics and the 
laboratory investigations of the SLE patients 
Patients 
(Sum=40) 
PON1 (U /ml) Anti-Apo A-I (U /l) 
r p r p 
Age 0.114 NS -0.041 NS 
Disease duration -0.2 NS -0.175 NS 
BMI 0.09 NS -0.19 NS 
Hemoglobin -0.309 NS -0.063 NS 
TLC 0.036 NS -0.309 NS 
Platelet -0.030 NS -0.183 NS 
ESR 0.009 NS 0.214 NS 
24 hour urinary protein -0.270 NS 0.196 NS 
TC 0.027 NS -0.109 NS 
TG 0.017 NS -0.163 NS 
HDL 0.010 NS -0.015 NS 
LDL 0.005 NS -0.088 NS 
Anti ds DNA 0.040 NS 0.296 NS 
C3 0.096 NS -0.316 0.047* 
C4 0.165 NS -0.416 0.008* 
*: significant (p < 0.05); NS: Non significant 
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Table 7: Correlation between PON1 activity, anti-Apo A-I, the doses and the duration of different 
drugs used 
Patients 
(n=40) 
PON1 (U/ml) Anti-Apo A-I (U/L) 
r p R p 
Correlation between PON1 activity, anti-Apo A-I, and the doses of different drugs used 
Corticosteroids 0.054 NS 0.197 NS 
Cyclophosphamide -0.267 NS 0.119 NS 
Azathioprine 0.009 NS -0.253 NS 
Antimalarials -0.032 NS 0.043 NS 
Correlation between PON1 activity, anti-Apo A-I, and the duration of different drugs used 
Corticosteroids 0.178 NS 0.075 NS 
Azathioprine 0.059 NS -0.304 NS 
Antimalarials 0.005 NS -0.305 NS 
NS: Non significant 
 
Table 8: PON1 activity levels in the presence and the absence of different disease manifestations 
Disease 
parameters Presence Absence Significance 
 Number of patients 
Mean 
PON1 ± SD 
U/ml 
Number of 
patients 
Mean 
PON1 ± SD 
U/ml 
p value 
Mucocutaneous 33 94.8 ± 7.9 7 100.8 ± 7.2 NS 
Constitutional 32 94.6 ± 8.3 8 101.2 ± 3.8 0.038* 
Frank arthritis 28 95.4 ± 8.2 12 96.9 ± 7.8 NS 
Nephritis 26 95.6 ± 7.3 14 96.5 ± 9.8 NS 
Serositis 16 95.1 ± 8.6 24 96.4 ± 7.8 NS 
CNS 12 90.9 ± 9.4 28 98.0 ± 6.5 0.03* 
Vasculitis 7 93.8 ± 8.5 33 96.3 ± 8.0 NS 
Hepatomegaly 10 96.5 ± 6.7 30 95.5 ± 9.1 NS 
Splenomegaly 5 97.1 ± 1.6 35 95.5 ± 9.1 NS 
*: significant (p < 0.05); NS: Non significant 
 
Table 9: Apolipoprotein A-I antibody levels in the presence and the absence of different disease mani-
festations 
Disease 
parameters Presence Absence Significance 
 Number of patients 
Mean 
Apo A-I ± SD 
(U/L) 
Number 
of patients
Mean 
Apo A-I ± SD 
(U/L) 
 
Mucocutaneous 33 33.9 ± 6.7 7 31.2 ± 7.7 NS 
Constitutional 32 33.7 ± 7.1 8 32.5 ± 6.3 NS 
Frank arthritis 28 33.2 ± 7.6 12 34.0 ± 5.2 NS 
Nephritis 26 34.0 ± 7.1 14 32.4 ± 6.6 NS 
Serositis 16 33.4 ± 8.6 24 33.5 ± 5.7 NS 
CNS 12 36.5 ± 8.5 28 32.1 ± 5.8 NS 
Vasculitis 7 37.5 ± 8.1 33 32.6 ± 6.4 NS 
Hepatomegaly 10 35.0 ± 4.8 30 33.2 ± 8.5 NS 
Splenomegaly 5 36.3 ± 3.0 35 33.2 ± 8.5 NS 
NS: Non significant 
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DISCUSSION 
Our study revealed statistically signifi-
cant lower plasma PON1 activity in SLE 
patients compared to the healthy controls. 
Thus, our patients are prone to atheroscle-
rosis and its complications. There are in-
creasing epidemiological evidences that 
PON1 protects against development of ath-
erosclerosis and is an independent risk fac-
tor for CVD (Fuhrman, 2012). In addition, 
decreased PON1 activity is associated with 
clinical atherothrombotic complications 
(Kiss et al., 2007). Furthermore, the athero-
protective function of PON1 has been also 
demonstrated in PON1 knock-out mice, 
which exhibited an accelerated atheroscle-
rosis (Marchegiani et al., 2012).  
The decreased PON1 activity in our pa-
tients may be a cause or a consequence of 
SLE. This issue remains unclear. As a 
cause, Tripi and his coworkers in (2006) 
concluded that low PON1 activity is inde-
pendently associated with SLE. On the con-
trary, reduced PON1 activity could be a 
consequence of inflammation and oxidative 
stress (Batuca et al., 2009). 
Assessment of PON1 activity in SLE 
patients showed conflicting results. Most 
studies reported decline of PON1 activity 
(Delgado Alves et al., 2002; Batuca et al., 
2007, 2009). The investigators assessed 
PON1 activity by paraoxon as a substrate in 
their assay. On the other hand, on using 
both phenyl acetate and paraoxon as sub-
strates in the assay in the same SLE patients 
(Tripi et al., 2006; Kiss et al., 2007), there 
was significant decline in PON1 activity 
when assessed by paraoxon. However, on 
assessment of PON1 activity by phenyl ace-
tate, there was significant increase in PON1 
activity in a study (Tripi et al., 2006), 
whereas, there was no significant change in 
PON1 activity in the other study. In our 
work we used phenyl acetate as a substrate 
for assessment of PON1 activity. 
These contrasting results of PON1 ac-
tivity levels in SLE may be attributed to the 
fact that PON1 activity differs greatly 
among ethnic groups. Inter-individual var-
iation in PON1 activity is under strong ge-
netic influence (Dasgupta et al., 2011) and 
pharmacological agents can also modulate 
PON1 activity (Precourt et al., 2011). On 
the other hand, the difference in the results 
of PON1 activity levels in the same patients 
may be attributed to genotype variation and 
polymorphism (Tripi et al., 2006; Kiss et 
al., 2007). Polymorphisms can generate op-
posite effects on PON1 activity depending 
on type of substrate used (Precourt et al., 
2011). 
Using phenyl acetate in our study as a 
substrate minimizes the role of genotype 
variation (Precourt et al., 2011). The differ-
ence between our results and the results of 
those who used phenyl acetate also in their 
studies (Tripi et al., 2006; Kiss et al., 2007) 
appears to be due to the exclusion of the 
individuals taking statins from our study. 
Statins has in general been associated with 
an increase in the PON1 serum activity 
measures (Camps et al., 2012). 
In our study, PON1 activity showed sta-
tistically significant negative correlation 
with SLE disease activity assessed by 
SLEDAI scores. Similar result was obtained 
between PON1 activity and British Isles 
Lupus Assessment Group (BILAG-2004) 
disease activity index. It has been reported 
that SLE activity is associated with deterio-
ration of antioxidant status (Batuca et al., 
2009). Increased oxidative stress inactivates 
PON1, and the decline in PON1 activity in 
turn augments oxidative stress. Therefore, 
the trio of disease activity, oxidative stress, 
and PON1 activity forms a vicious circle 
(Camps et al., 2012; Li et al., 2012) and this 
explains the negative correlation between 
PON1 activity and SLEDAI. 
In contrast to our results, Kiss and his 
coworkers in 2007 found no correlation be-
tween PON1 activity and SLEDAI. This 
may be attributed to the relatively lower 
SLEDAI scores of the patients included in 
their study (2) versus (7.9) in our study. 
There was a statistically significant 
negative correlation between SLICC/ACR 
damage index scores and PON1 activity in 
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our study. Our data is consistent with a pre-
vious report (Batuca et al., 2009). The re-
ported oxidative stress in SLE can damage 
macromolecules and can exacerbate in-
flammation leading to tissue damage (Shah 
et al., 2011). This may be an explanation 
for this result. 
In this study, statistically significant dif-
ferences were obtained between the PON1 
levels in the presence and absence of con-
stitutional and CNS manifestations only. To 
our knowledge, this is the first study to ad-
dress this relationship in SLE. On the other 
hand, Tripi et al., (2006) found decreased 
(though non-significant) PON1 activity lev-
els in lupus nephritis patients compared to 
those without lupus nephritis. To document 
possible relationships between PON1 ac-
tivity and other clinical manifestations of 
SLE appears to need large samples as SLE 
is a heterogeneous disease. 
Apolipoprotein A-I is an important 
component of HDL and it has cardioprotec-
tive effects (Eren et al., 2012). Autoanti-
bodies directed to Apo A-I molecules may 
inhibit their normal functions (Hahn, 2010). 
These antibodies may be present in general 
population but in low titers and it may be 
related to the vascular and immune ageing 
processes (Batuca et al., 2007). 
In this study, there was a statistically 
significant higher anti-Apo A-I antibody 
levels in SLE patients as compared to the 
healthy controls. These antibodies have 
been identified in SLE (O’Neill et al., 
2010). However, there is paucity of infor-
mation about its exact pathophysiological 
role (Hahn, 2010). Anti-Apo A-I antibody 
production may be explained by the fact 
that autoantibodies production against mul-
tiple self antigens is considered as a hall-
mark of SLE (Joo et al., 2012). In autoim-
mune diseases, oxidative stress is the major 
event causing structural modifications of 
proteins with consequent appearance of ne-
oepitopes which can become targets of au-
toimmune reactions, thus sustaining the in-
flammatory mechanisms involved in endo-
thelial dysfunction and plaque development 
(Profumo et al., 2011). 
These autoantibodies may lead to Apo 
A-I dysfunction. Apo A-I normally contrib-
utes in the removal of damaged and apo-
ptotic endothelial cells. Thus, anti-Apo A-I 
antibodies that inhibit these normal func-
tions could predispose to autoimmunity and 
may play a role in the pathogenesis of SLE. 
Even if these antibodies arise later, in the 
development of the disease, and even if dis-
ease is already established, these antibodies 
may promote a vicious cycle perpetuating 
the pathological process underlying the dis-
ease (Shoenfeld et al., 2007; Hahn, 2010). 
Apolipoprotein A-I antibodies can af-
fect atherosclerosis and thrombosis inde-
pendent of autoimmunity (Hahn, 2010). It 
could represent an emerging CVD risk fac-
tor and an independent predictor of major 
CVD events (Vuilleumier et al., 2010). The 
presence of these antibodies in our patients 
might have exposed them to accelerated 
atherosclerosis as they lose their atheropro-
tection mediated by Apo A-I. These anti-
bodies can also affect the normal atheropro-
tective function of HDL, and the formed 
dysfunctional HDLs are proinflammatory 
(Hahn, 2010).  
Our study revealed statistically signifi-
cant lower C3 and C4 levels in SLE patients 
compared to the healthy controls. However, 
the mean values of C3 and C4 in the SLE 
patients and controls were within the nor-
mal range. Thus, there may be a mild de-
gree of complement activation. Negative 
correlation was obtained between anti-Apo 
A-I antibody with C3 and C4 levels. Circu-
lating immune complexes have been corre-
lated with complement activation and auto-
antibody profiles in SLE (Mathsson et al., 
2007). This may be a potential explanation 
for the activation and consumption of C3 
and C4 associated with the increase in pro-
duction of autoantibodies against Apo A-I 
in our patients. 
There was a significant positive correla-
tion between anti-Apo A-I antibody and 
SLE disease activity assessed by SLEDAI 
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scores in our patients. In SLE, levels of cer-
tain antibodies such as anti-dsDNA fre-
quently correlate with the disease activity 
(O’Neill et al., 2010). Similarly, other stud-
ies reported association between anti-Apo 
A-I antibody and SLE disease activity using 
other different scoring systems than 
SLEDAI. Significant positive correlation 
between anti-Apo A-I antibody levels, and 
SLE disease activity assessed both by 
BILAG (Batuca et al., 2007) and by the Eu-
ropean Consensus Lupus Activity Meas-
urement (ECLAM) in their German patients 
(Shoenfeld et al., 2007) have been reported. 
There was a statistically significant pos-
itive correlation between SLICC/ACR 
scores and anti–Apo A-I antibody levels in 
our study. Our results confirm the findings 
of others (Batuca et al., 2009). This can be 
explained by the formation of antibody–
antigen complexes that can attach to tissues, 
fix complement, and cause its damage 
(Hahn, 2010). 
Compared to controls, our patients have 
dyslipidemia in the form of reduced levels 
of HDL and elevated levels of TC, TG, and 
LDL. This pattern of dyslipidemia is asso-
ciated with adverse CVD risk in the general 
population (Ji et al., 2011). 
From the above discussion, our patients 
appear to be in a proatherogenic state. Tra-
ditional risk factors involved in the patho-
genesis of atherosclerosis in our patients 
include dyslipidemia, corticosteroid admin-
istration and hypertension. SLE-related risk 
factors in our patients include: immune sys-
tem involvement (anti-Apo A-I antibody 
production), and oxidative stress (reduced 
PON1 activity) (Skaggs et al., 2012). 
Increasing evidence has highlighted the 
role of oxidative stress in both SLE as well 
as atherosclerotic CVD. However, the mo-
lecular bases of the interaction between in-
creased oxidative stress, SLE and athero-
sclerosis remain unclear (Li et al., 2012). 
This study may provide a plausible explana-
tion for these clues. PON1 physiologically 
plays an important role in decreasing oxida-
tive stress and atherosclerosis risk. It ac-
counts for most of the capacity of HDL to 
prevent oxidation of LDL (Fuhrman, 2012). 
So, the reduced PON1 activity in our pa-
tients might have a deleterious effect on the 
protective function of HDL. SLE is associ-
ated with intense antibody production and a 
possible mechanism for the reduced antiox-
idant PON1 activity may be the autoanti-
body production against Apo A-I present in 
our patients (Srivastava et al., 2011). The 
statistically significant negative correlation 
between PON1 and anti-Apo A-I antibody 
in the present study together with other re-
search groups (Batuca et al., 2007, 2009) 
highlighted this concept. Our results sug-
gest the presence of a vicious circuit be-
tween PON1 activity and anti-Apo A-I an-
tibody. Reduced PON1 activity affects 
HDL functions and this enhances the oxida-
tive stress. Oxidative stress leads to the 
formation of new antigens which in turn 
enhances the humoral response leading to 
the production of autoantibodies including 
anti-Apo A-I antibodies. Anti-Apo A-I an-
tibodies target PON1 reducing its activity 
(Srivastava et al., 2011; Fuhrman, 2012). 
Such a vicious circuit with its components 
maintains oxidative stress and subsequent 
SLE-related pro-atherogenic state. 
Diminished HDL levels have been re-
cognized as an independent risk factor for 
CVD. However, there is an increasing evi-
dence that HDL quality may be as im-
portant as its quantity. The concept of "dys-
functional HDL" or "proinflammatory 
HDL" is an emerging issue. Dysfunctional 
HDL converts a positive force protecting 
arteries to a negative one, enhancing ather-
ogenesis (Otocka-Kmiecik et al., 2012). 
Among the factors that convert HDL into 
"dysfunctional HDL" is the decrease of the 
major antioxidant enzyme PON1. Another 
major structural and functional component 
of HDL is Apo A-I. Autoantibodies against 
Apo A-I may lead to Apo A-I dysfunction 
with secondary HDL dysfunction (McMah-
on, 2009; Hahn, 2010). 
HDL may be affected in our SLE pa-
tients in the same manner. The two main 
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components that accounts for most of the 
protective functions of HDL are affected. 
PON1 activity is diminished and Apo A-I 
are targeted by an anti-Apo A-I antibodies. 
So, our patients appear to have dysfunc-
tional HDL. Dysfunctional HDL is another 
pro-atherogenic factor (McMahon et al., 
2009) in our SLE patients. 
Finally, over the next few years, the two 
SLE related risk factors of atherosclerosis 
in this study anti-Apo A-I antibodies and/or 
PON1 activity may be recommended as a 
routine strategy to stratify patients for risk 
of accelerated atherosclerosis. 
 
CONCLUSION 
There is decreased PON1 activity and 
formation of anti-Apo A-I antibodies in fe-
male patients with SLE. SLE-disease activi-
ty assessed by SLEDAI and SLE disease 
related organ damage assessed by 
SLICC/ACR damage index are negatively 
correlated with PON1 activity and positive-
ly correlated with anti-Apo A-I antibodies. 
PON1 activity and anti-Apo A-I antibodies 
might be involved in the pathogenesis of 
atherosclerosis in SLE patients. 
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